Scancell Hldgs (UK) Today

SCLP Stock   10.75  0.10  0.92%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Over 85

 
High
 
Low
Very High
Scancell Hldgs is selling for under 10.75 as of the 18th of December 2024; that is 0.92 percent decrease since the beginning of the trading day. The stock's lowest day price was 10.5. Scancell Hldgs has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 18th of November 2024 and ending today, the 18th of December 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
Category
Healthcare
Classification
Health Care
Scancell Hldgs is entity of United Kingdom. It is traded as Stock on LSE exchange. The company has 929.6 M outstanding shares. More on Scancell Hldgs Plc

Moving against Scancell Stock

  0.680QY4 Las Vegas SandsPairCorr
  0.470QYD Yum BrandsPairCorr
  0.430HKE Axon EnterprisePairCorr
  0.40R15 SoftBank Group CorpPairCorr
  0.330I9F Digital Realty TrustPairCorr

Scancell Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Scancell Hldgs' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Scancell Hldgs or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
CEO DirectorPhil LHuillier
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care (View all Sectors)
Scancell Hldgs' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Scancell Hldgs' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Debt Levels
Scancell Hldgs can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Scancell Hldgs' financial leverage. It provides some insight into what part of Scancell Hldgs' total assets is financed by creditors.
Liquidity
Scancell Hldgs cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. Scancell Hldgs Plc has accumulated 19.87 M in total debt. Debt can assist Scancell Hldgs until it has trouble settling it off, either with new capital or with free cash flow. So, Scancell Hldgs' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Scancell Hldgs Plc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Scancell to invest in growth at high rates of return. When we think about Scancell Hldgs' use of debt, we should always consider it together with cash and equity.

Capital Expenditures

108,736
Scancell Hldgs Plc (SCLP) is traded on London Exchange in UK and employs 61 people. Scancell Hldgs is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 103.21 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Scancell Hldgs's market, we take the total number of its shares issued and multiply it by Scancell Hldgs's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Scancell Hldgs Plc operates under Biotechnology sector and is part of Health Care industry. The entity has 929.6 M outstanding shares. Scancell Hldgs generates negative cash flow from operations
Check Scancell Hldgs Probability Of Bankruptcy
Ownership Allocation
Scancell Hldgs Plc shows a total of 929.6 Million outstanding shares. 30% of Scancell Hldgs Plc outstanding shares are owned by institutional holders. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Scancell Ownership Details

Scancell Hldgs Plc Risk Profiles

Although Scancell Hldgs' alpha and beta are two of the key measurements used to evaluate Scancell Hldgs' performance over the market, the standard measures of volatility play an important role as well.

Scancell Stock Against Markets

Be your own money manager

Our tools can tell you how much better you can do entering a position in Scancell Hldgs without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Volatility Now

   

Portfolio Volatility

Check portfolio volatility and analyze historical return density to properly model market risk
All  Next Launch Module

Scancell Hldgs Corporate Management

Elected by the shareholders, the Scancell Hldgs' board of directors comprises two types of representatives: Scancell Hldgs inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Scancell. The board's role is to monitor Scancell Hldgs' management team and ensure that shareholders' interests are well served. Scancell Hldgs' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Scancell Hldgs' outside directors are responsible for providing unbiased perspectives on the board's policies.
Sathijeevan NirmalananthanChief OfficerProfile
Mandeep SehmiHead DevelopmentProfile
Fayaz MasterHead OperationsProfile
Sally AdamsExecutive OfficerProfile
Adrian ParryHead ManufacturingProfile

Additional Tools for Scancell Stock Analysis

When running Scancell Hldgs' price analysis, check to measure Scancell Hldgs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scancell Hldgs is operating at the current time. Most of Scancell Hldgs' value examination focuses on studying past and present price action to predict the probability of Scancell Hldgs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Scancell Hldgs' price. Additionally, you may evaluate how the addition of Scancell Hldgs to your portfolios can decrease your overall portfolio volatility.